DS-8201 has been granted Breakthrough Therapy designation for the treatment of patients with HER2-positive, locally advanced or metastatic breast cancer who have been treated with trastuzumab and pertuzumab and have disease progression after ado-trastuzumab emtansine (T-DM1), and Fast Track designation for the treatment of HER2-positive unresectable and/or metastatic breast cancer in patients who have progressed after prior treatment with HER2-targeted therapies including T-DM1 by the . Food and Drug Administration (FDA).
Delivering healthcare in the future will require innovative solutions, collaboration, investment and commitment. With a backdrop of increasing costs, demand and complexity, our challenge is significant. Onelink is dedicated and resourced to contribute to this new world by delivering transformational change in the supply chain; change that will unlock new savings and improve quality. And, while we work to deliver innovation and value, we will not lose sight of our daily commitments. Commitments to all of our customers and ultimately their customers, the patients.
Donna’s previous roles include being an executive team member of Abzena plc as SVP IP Commercial and Legal Affairs where she was responsible for the legal IP and transactional activity, including partnering deals worth over $700m biodollar value plus royalties for antibody and antibody drug conjugate technology; she was COO and executive board member of Stabilitech,ensuring the company was commercially facing, client focussed and using appropriate pricing models when negotiating and concluding agreements for its thermal stabilisation platform. She was also partner of ProPharma Partners, the multi-national commercial and development consulting group; UCL where she headed up the BioPharm Technology Transfer side of UCL Ventures and BTG.